Erythropoietin

Erythropoietic Protoporphyria - Pipeline Insight, 2020

Retrieved on: 
Monday, February 24, 2020
Medicine, Branches of biology, Organ systems, Porphyrias, RTT, Erythropoietic protoporphyria, Erythropoietin

DUBLIN, Feb. 24, 2020 /PRNewswire/ -- The "Erythropoietic Protoporphyria - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 24, 2020 /PRNewswire/ -- The "Erythropoietic Protoporphyria - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Erythropoietic Protoporphyria pipeline landscape is provided, which includes the disease overview and Erythropoietic Protoporphyria treatment guidelines.
  • The assessment part of the report embraces in-depth Erythropoietic Protoporphyria commercial assessment and clinical assessment of the Erythropoietic Protoporphyria pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Erythropoietic Protoporphyria emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Erythropoietic Protoporphyria?

Global Recombinant Cell Culture Supplements Market, Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 3, 2020
Health, Biotechnology, Branches of biology, Biology, Biotechnology, Life sciences, Cytokines, Alternatives to animal testing, Cell biology, Cell culture, Erythropoietin

The "Global Recombinant Cell Culture Supplements Market: Focus on Product Type, Applications, 5 Regional Data, 23 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Recombinant Cell Culture Supplements Market: Focus on Product Type, Applications, 5 Regional Data, 23 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.
  • The recombinant cell culture supplements market analysis projects the market to grow at a significant CAGR of 12.93% during the forecast period, 2019-2029.
  • The recombinant cell culture supplements market generated $258.8 million in revenue in 2018, in terms of value.
  • The recombinant cell culture supplements market growth has been primarily attributed to the major drivers in this market such as advantages offered by recombinant cell culture supplements and the promising impact displayed by them in culturing cells act as drivers for the growth of the market.

Global Chemotherapy-Induced Anemia Market Spotlight Report 2019: Pfizer's Epogen Biosimilar Retacrit Launches at 33% Off in a US Market where Amgen's Already Competitive - ResearchAndMarkets.com

Retrieved on: 
Monday, December 2, 2019
Health, Clinical trials, Medicine, Health, Clinical medicine, RTT, Growth factors, Antineoplastic drugs, Oncology, Amgen, Chemotherapy, Anemia, Erythropoietin, Clinical trial

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy.
  • The proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
  • Amgen leads industry sponsors with the highest number of clinical trials for CIA, followed by Johnson & Johnson.

The Erythropoietin Stimulating Agents Market in Latin America (2019-2027): Data on Epoetin-Alfa, Epoetin-Beta, Epoetin-Theta, Darbepoetin-Alfa, and Other ESAs

Retrieved on: 
Wednesday, November 27, 2019
Branches of biology, Medicine, Medical specialties, Growth factors, RTT, Cytokines, Erythropoietin, Hematopoiesis, Erythropoiesis-stimulating agent, Erythropoiesis

DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 27, 2019 /PRNewswire/ -- The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America erythropoiesis stimulating agents (ESA) market reached USD 319.2 million in 2018 and is expected to reach USD 533.92 million by 2027, by registering a CAGR of 6.03%, across the region.
  • The demand for erythropoiesis stimulating agents is increasing on the back of the rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin.
  • Brazil is slated to account for a share of 44.77% and reach USD 239.03 million by 2027 in the erythropoiesis stimulating agents market.

Latin America's $534M Erythropoietin Stimulating Agents Market, 2019-2027: Demand Analysis & Opportunity Evaluation - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 26, 2019
Health, Pharmaceutical, Branches of biology, Medicine, Medical specialties, Growth factors, RTT, Erythropoiesis-stimulating agents, Cytokines, Erythropoietin, Erythropoiesis

The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Latin America Erythropoietin Stimulating Agents Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America erythropoiesis stimulating agents (ESA) market reached USD 319.2 million in 2018 and is expected to reach USD 533.92 million by 2027, by registering a CAGR of 6.03%, across the region.
  • The demand for erythropoiesis stimulating agents is increasing on the back of the rising demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin.
  • Brazil is slated to account for a share of 44.77% and reach USD 239.03 million by 2027 in the erythropoiesis stimulating agents market.

RegeneRx's Tβ4 Significantly Reduces Damage in Ischemic Acute Kidney Injury Model

Retrieved on: 
Monday, November 18, 2019
Branches of biology, Medical specialties, Anatomy, Kidney diseases, Organ failure, Acute kidney injury, Kidney, Erythropoietin, Ischemia

In this study, researchers reported that administration of T4 to animals with induced kidney injury significantly reduced ischemic acute kidney injury.

Key Points: 
  • In this study, researchers reported that administration of T4 to animals with induced kidney injury significantly reduced ischemic acute kidney injury.
  • "This paper validates the tissue protection and repair properties of T4 in the kidney as previously demonstrated by research teams around the world in the heart, liver, lungs and brain.
  • What is new in this paper is that T4 also appeared to modulate renal redox status (the balance of specific biological processes affecting normal kidney function).
  • The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023 Featuring Shenyang Sunshine Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
Monday, September 16, 2019
Health, Pharmaceutical, Cities in China, Branches of biology, Growth factors, Medicine, Shenyang, Recombinant, Erythropoietin

The "Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • Considering the high growth rate of the Recombinant Human Thrombopoietin market, Recombinant Human Thrombopoietin products by other enterprises will probably be approved to be launched in China in the next few years.
  • In 2005, Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (trade name: TPIAO) was approved to be sold in China.
  • 2 Sales of Recombinant Human Thrombopoietin in China, 2013-2017
    2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2013-2017
    3 Analysis of Major Manufacturer of Recombinant Human Thrombopoietin in China, 2013-2017
    3.2 Shenyang Sunshine Pharmaceutical Co., Ltd.
    3.2.2 Sales of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China
    4 Prices of Recombinant Human Thrombopoietin in China, 2017-2018
    4.1 Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
    5 Prospect of China's Recombinant Human Thrombopoietin Market, 2019-2023
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190916005636/en/

Venous Thromboembolism Treatment Market: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029

Retrieved on: 
Tuesday, July 2, 2019
Medical specialties, Hematology, Medicine, Branches of biology, Erythropoietin, Embolism, Venous thrombosis

the analyst has conducted a study on venous thromboembolism treatment through the analysis and forecast of the venous thromboembolism treatment market in its publication titled 'Venous Thromboembolism Treatment Market: Global Industry Analysis 2014 2018 and Opportunity Assessment 2019 2029.'

Key Points: 
  • the analyst has conducted a study on venous thromboembolism treatment through the analysis and forecast of the venous thromboembolism treatment market in its publication titled 'Venous Thromboembolism Treatment Market: Global Industry Analysis 2014 2018 and Opportunity Assessment 2019 2029.'
  • This report on the venous thromboembolism treatment market covers the various key factors influencing the demand and supply of venous thromboembolism treatment over the next several years.
  • The venous thromboembolism treatment market study elaborates on the growth drivers, restraints, various market trends, and opportunities for participants in the venous thromboembolism treatment market.
  • Different key players in the venous thromboembolism treatment market manufacture various products for the treatment of venous thromboembolism.

Chronic Renal Failure Therapeutics Market Worth USD 3.17 Billion, at 5% CAGR during 2019-2023 | Technavio

Retrieved on: 
Tuesday, June 18, 2019
Health, Cardiology, Pharmaceutical, Research, Diabetes, Science, Branches of biology, Medical specialties, Anatomy, Organ failure, RTT, Kidney diseases, Hypoxia-inducible factors, Chronic kidney disease, Erythropoietin, Kidney failure, HIF prolyl-hydroxylase inhibitor

View the full release here: https://www.businesswire.com/news/home/20190618005464/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190618005464/en/
    Technavio has published a new market research report on the global chronic renal failure therapeutics market from 2019-2023.
  • (Graphic: Business Wire)
    Free sample report contains market size and forecast, drivers, challenges, trends, and more Request for Free Sample @ https://www.technavio.com/talk-to-us?report=Global+Chronic+Renal+Failure...
    Global chronic renal failure therapeutics market: Development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors
    ESAs have been the standard of treatment for anemia in patients with chronic renal failure.
  • Global chronic renal failure therapeutics market: Segmentation analysis
    This market research report segments the global chronic renal failure therapeutics market by product (antihypertensive therapeutics, antianemia therapeutics, and others), and geographic regions (North America, Europe, Asia, and ROW).
  • Global chronic renal failure therapeutics market: Rising prevalence of chronic renal failure
    Some of the major risk factors involved in the development of chronic renal failure are diabetes, heart disease, high blood pressure, a family history of kidney failure, and obesity.

Kindred Biosciences Announces First Quarter 2019 Financial Results

Retrieved on: 
Thursday, May 9, 2019
Life sciences, Articles, Biotechnology, Specialty drugs, Cytokines, Erythropoietin, Biopharmaceutical

SAN FRANCISCO, May 9, 2019 /PRNewswire/ --Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2019 and provided updates on its programs.For the first quarter 2019, KindredBio reported net product revenues of $0.5 million and a net loss of $16.1 million, or $0.42 per share.

Key Points: 
  • SAN FRANCISCO, May 9, 2019 /PRNewswire/ --Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2019 and provided updates on its programs.For the first quarter 2019, KindredBio reported net product revenues of $0.5 million and a net loss of $16.1 million, or $0.42 per share.
  • Results from the study are expected in the third quarter, with a pivotal study expected to commence by year-end.
  • KindredBio announced positive topline results from a pilot field effectiveness study of its feline recombinant erythropoietin in January 2019.
  • The cost of product sales totaled $92,000 in the first quarter of 2019, resulting in a gross margin of 82%.